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Approximately 60% of hepatitis A virus infections in 
Germany occur in persons without a travel history to dis-
ease-endemic areas and for whom sources of infection are 
unknown. Recommendation of pretravel vaccination fails to 
prevent the remaining imported infections. Using enhanced 
surveillance in 2007–2008, we analyzed epidemiologic 
patterns of hepatitis A in Germany and appropriateness 
and adequacy of current immunization recommendations. 
Young patients with a migration background who had visited 
friends and family in their ancestral countries accounted for 
most imported cases. Phylogenetic analysis showed high 
diversity of sequence data and clustering of strains with 
similar regions of origin or patient migration backgrounds. 
Virologic  ﬁ   ndings are compatible with those of low-inci-
dence countries, where virtually all infections are directly or 
indirectly imported from other regions. Germans with a mi-
gration background are seen as a special risk group so far 
insufﬁ  ciently reached by pretravel vaccination advice. 
A
fter decades of steady decreases (1), annual cases of 
hepatitis A in Germany in 2005 and 2006 remained 
at a relatively constant level (≈1,200 reported cases, inci-
dence 1.5/100,000 population). The actual number of infec-
tions estimated on the basis of prevalence of immunoglob-
ulin (Ig) G against hepatitis A virus (HAV) in Germany 
is presumed to be higher. Mild or subclinical infections, 
especially in children, are not detected by surveillance (2). 
A seasonal pattern is observed every year; most reported 
cases occur in late summer and fall.
In Sweden, notiﬁ  cation data indicate that most cases 
are imported (3). However, ≈60% of reported cases in Ger-
many occur in persons who deny recent travel to disease-
endemic areas (4), similar to the situation in France (5). 
Exact sources and risk factors for these autochthonous in-
fections in Germany often remain unknown because rou-
tine surveillance data lack detail.
Molecular markers, such as nucleotide sequence pat-
terns, have proven useful for elucidating modes and chains 
of transmission or identifying new risk groups and factors. 
These factors would otherwise be difﬁ  cult to determine be-
cause of the long incubation period (15–50 days) for hepa-
titis A and often unapparent connections between persons 
involved in outbreaks (6).
A 1-year study was initiated by the Robert Koch Insti-
tute (RKI) to characterize and compare imported and non-
imported HAV infections in Germany and determine HAV 
genotype distribution and sources of infection. We assessed 
whether the virus is endemic among certain (unrecognized) 
risk groups, whether (and which) imported infections play 
a role in secondary autochthonous infections, and which 
population groups should be targeted for speciﬁ  c preven-
tion approaches (e.g., immunization).
Methods
Routine Epidemiologic Data
The study was conducted from the 14th calendar week 
of 2007 through the 13th calendar week of 2008. Acute hep-
atitis A has been a notiﬁ  able disease in Germany for many 
years. Since 2001, laboratories have reported infections (test 
results indicative of acute HAV infection, detection of spe-
ciﬁ  c IgM in serum, or detection of HAV RNA in serum or 
feces by PCR) to local health departments. These depart-
ments collect information on case-patients (age, sex, travel 
history, date of onset, clinical symptoms, duration of hospi-
talization), take preventive measures to avoid further spread 
(including recommending vaccination of contacts, barring 
infected food handlers from working), and report standard 
case information electronically to state health authorities and 
RKI in a form in which names and addresses are removed. 
Data can be grouped on all levels to indicate outbreaks.
Epidemiology of Hepatitis A Virus 
Infections, Germany, 2007–2008 
Mirko S. Faber, Klaus Stark, Susanne C. Behnke, Eckart Schreier, and Christina Frank
RESEARCH
1760  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 11, November 2009
Author afﬁ  liation: Robert Koch Institute, Berlin, Germany
DOI: 10.3201/eid1511.090214Hepatitis A Infections, Germany, 2007–2008
Additional Epidemiologic Data
To transcend standard information obtained for each 
reported infection and add a virologic perspective, we col-
lected additional case information on all HAV infections 
in Germany over a 1-year period. The 16 state health de-
partments in Germany were requested to participate and 
coordinate distribution and collection of questionnaires 
to all local public health departments. These departments 
recorded additional case information obtained during 
routine case investigations on paper forms (additional 
case information sheets). Data included details of trav-
el, concurrent health conditions, and potential migration 
background. These investigations consisted of telephone 
interviews with patients (rarely with their physicians as 
proxies). Completed forms were sent to RKI without 
names and addresses but did contain case codes. Accom-
modations other than hotels were deﬁ  ned as those presum-
ably involving closer contact with the local population or 
exposure to food prepared under potentially suboptimal 
hygienic conditions (e.g., private accommodations, hos-
tels, or campgrounds).
Persons with a migration background were deﬁ  ned as 
those who moved to Germany after 1949 as non-German 
nationals, children born in Germany to non-German na-
tionals, or children born to at least 1 parent belonging to 
either of these groups. Adults were deﬁ  ned as persons >18 
years of age.
Laboratory Data
We obtained serum samples from >10% of persons 
with HAV infections diagnosed in Germany during the 
study. To facilitate sequencing and phylogenetic analysis 
of a representative selection of HAV strains causing infec-
tions in Germany during the study, we asked >120 large 
private laboratories, university clinics, and hospitals in 
Germany to provide serum samples for patients for whom 
IgM against HAV was detected at their facilities. Samples 
were either sent to RKI immediately or stored at –20°C and 
sent in larger batches.
Collation of Data Sources
Information recorded on paper forms was entered into 
a database and matched to electronically transmitted routine 
data by case codes. All symptomatic cases reported from 
participating states were analyzed. Clinical specimens were 
matched to questionnaire and surveillance data according 
to anonymous patient information (year and month of birth, 
sex, crude area of residence, date of blood sampling) pro-
vided by the laboratories.
Isolation and Sequencing of HAV RNA
HAV RNA was isolated from serum samples by us-
ing a Viral RNA Mini Kit (QIAGEN, Hilden, Germany). 
Reverse transcription and ﬁ  rst-round ampliﬁ  cation of the 
capsid protein (VP1)/2A junction region of HAV were per-
formed by using a Onestep RT-PCR Kit (QIAGEN) and 
primers (Table 1).
Nested PCR was performed by using the HotStarTaq 
Master Mix Kit (QIAGEN). Puriﬁ  ed products of the nested 
PCR (forward and reverse strands) were sequenced by us-
ing a 3130x ABI Prism Genetic Analyzer and a BigDye 
Terminator version 3.1 Cycle Sequencing Kit (PE Applied 
Biosystems, Weiterstadt, Germany). 
Statistical Analysis
Sequences were processed by using Lasergene Seq-
Man Pro software (DNASTAR, Inc., Madison, WI, USA), 
aligned by using the ClustalW algorithm (7), and opti-
mized manually. Phylogenetic trees were constructed by 
using all available HAV sequences from obtained HAV 
IgM–positive samples (including HAV sequences from 
cases not reported). Sequence statistical and phylogenetic 
analyses were conducted by using MEGA4 (8). Sequences 
obtained are referenced in GenBank under accession nos. 
EU416232–EU416273 and EU825848–EU825918. For 
statistical analysis, we used Microsoft Excel 2003 (Micro-
soft, Redmond, WA, USA), SPSS version 15.0 (SPSS Inc., 
Chicago, IL, USA), and STATA version 10.1 (StataCorp, 
College Station, TX, USA).
Results
Study Population
A total of 1,213 HAV infections were reported. Among 
them, 952 (78.5%) were in patients with clinical symptoms 
consistent with acute hepatitis A. Of the 16 states in Ger-
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Table 1. Primers used for detection of HAV RNA by nested RT-PCR in clinical specimens from patients in Germany, 2007–2008* 
Primer Sequence  (5ƍ ĺ 3ƍ)  Orientation, position, and use 
HAV6a  GGA AAT ATT CAG ATT AGG YTG CCT TGG T 
HAV6b  GGG AAC ATT CAG ATY AGA TTG CCW TGG T 
Sense, 2793–2820, reverse transcription and first-round PCR 
HAV17a  CAA AGC TCT AGT RTC AGC AGT AAT TCC 
HAV17b  CAA AGC CCT AGT RTC AGC AGT CAC TCC 
Antisense, 3300–3326, reverse transcription and first-round PCR
HAV8a  CTT TTG GAT TKG TTT CYA TTC AGA TTG C  Sense, 2882–2908, nested PCR and sequencing 
HAV7a  GAA AAC TTC ATT ATT TCA TGM TCY TCW GT  Antisense, 3264–3292, nested PCR and sequencing 
*HAV, hepatitis A virus; RT-PCR, reverse transcription–PCR. Positions in the HAV genome are given according to strain HM-175 (GenBank accession no.  
M14707). RESEARCH
many, 13 participated in the intensiﬁ  ed surveillance and 
contributed 1,037 (85.5%) of all reported infections and 
816 (86%) of all reported symptomatic cases (maximal de-
nominator for analysis). Additional case information sheets 
were available for 571 (70%) symptomatic cases. Serum 
samples positive for IgM against HAV were available for 
189 (23.2%) cases; 95 (11.6%) were PCR positive.
A total of 74.6% of the cases were reported as single 
cases; the remainder were in recognized clusters. Among 
case-patients, 47.1% were male (Table 2); age range <1 to 
90 years (median 32 years). Among nonadults, 81.1% were 
reported to have had jaundice. Among adults, the propor-
tion of persons with jaundice decreased with age to 40.6% 
in persons >60 years of age.
Of case-patients, 46.4% were hospitalized for a median 
of 6 days (range 1–28 days). Among those with jaundice, 
no clear trend for age was found in 50.2% who were hos-
pitalized. Among those without jaundice, the proportion of 
those hospitalized increased among persons >60 years of 
age (56.5%) when compared with that of younger persons 
(31.3%, relative risk [RR] 1.81, 95% conﬁ  dence interval 
[CI] 1.35–2.41). Among those employed, absences from 
work ranged from 2 to 32 work days (median 6 days).
Overall, 43.6% of the infections were imported (i.e., 
infection acquired while traveling outside Germany). Non-
adults (60.6% imported; p<0.001) and male patients (48.1% 
imported; p = 0.018) were overrepresented.
A migration background was reported by 42.2% of 
case-patients (78.8% of nonadults and 19.1% of adults), 
of whom 64.8% had been born in Germany. Among 
migration backgrounds, Turkey was reported most fre-
quently (48.5%), followed by the former Yugoslavia 
(11.9%), southern and Southeast Asia (9.7%), and the for-
mer USSR (8.8%). Nonadults with a migration background 
lived with a larger number of household members (range 
1–11 persons in addition to the case-patient, median 4) than 
those without a migration background (range 1–6 persons, 
median 3). Among adult case-patients, 5.2% were profes-
sional food handlers.
Imported Infections and Comparison 
with Autochthonous Infections
Among known destinations, Turkey (35.6%) was 
reported most frequently, followed by the former Yugo-
slavia, Egypt, and Spain (Table 3). Most affected case-
patients (63.9%), especially nonadults (82%), had not 
traveled for vacation or business but had visited friends or 
family. Median duration of travel preceding infection was 
29 days (range 1–180 days). Accommodations other than 
hotels (e.g., staying with friends or family) predominated 
(73.1%), especially among those visiting Turkey (91.9%) 
and the former Yugoslavia (94.1%). A total of 92.9% of 
those infected in Turkey and 76.2% of those infected in 
countries of the former Yugoslavia had matching migra-
tion backgrounds; only 3 (16.7%) of those infected in 
Egypt had matching migration backgrounds. Of case-
patients with migration backgrounds who had become 
infected in these ancestral countries, 75.9% from Turkey, 
87.5% from the former Yugoslavia, and 100% from Egypt 
were nonadults.
Imported infections were most likely to cause disease 
from August through October, and a prolonged wave of 
autochthonous infections then followed from October 
through March (Figure 1). Among imported infections, 
children and persons <20 years of age were overrepre-
sented, (70.2% from August through October vs. 33.9% 
in other months; p>0.001). Among autochthonous cases, 
incidence in children and persons <20 years of age in-
creased 62% from September through February com-
pared with March through August. Autochthonous cases 
in adults >40 years of age were almost evenly spread 
throughout the year.
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Table 2. Characteristics of 816 patients tested for hepatitis A virus infection, Germany, 2007–2008 
Characteristic No. (%) patients 
No. (%) patients with additional 
case information 
No. (%) patients with serum 
samples available 
Sex 
  M  384 (47.1)  266 (46.7)  101 (53.7) 
  F  431 (52.9)  304 (53.3)  87 (46.3) 
Age, y 
  <1–9  168 (20.6)  136 (23.9)  44 (23.3) 
  10–19  138 (16.9)  107 (18.8)  32 (16.9) 
  20–39  157 (19.3)  119 (20.9)  43 (22.8) 
  40–59  180 (22.1)  116 (20.4)  39 (20.6) 
>60 172 (21.1)  92 (16.1)  31 (16.4) 
Hospitalized
  Yes  377 (46.4)  266 (46.6)  87 (46.3) 
  No  436 (53.6)  305 (53.4)  101 (53.7) 
Imported infection 
  Yes  346 (43.6)  269 (47.1)  89 (47.8) 
  No  447 (56.4)  302 (52.9)  97 (52.2) Hepatitis A Infections, Germany, 2007–2008
Case-patients with autochthonous infections were 
older than case-patients with imported infections and less 
likely to have migration backgrounds (Figure 2). Almost all 
patients >60 years of age had autochthonous infections. 
A migration background was more likely among per-
sons with imported infections; 52.8% of case-patients had 
a background of migration from Turkey. However, 23% 
of persons with autochthonous infections had a migration 
background (Table 4). Patients with autochthonous infec-
tions were older; 56.4% persons with nonimported cases 
were >40 years of age and 31.1% were >60 years of age, 
compared with only 24% and 7.5%, respectively, of per-
sons of the same ages with cases of imported infections. 
Case-patients with imported infections were also slightly 
more likely to be male and part of case clusters than were 
autochthonous case-patients.
Close contacts of 58.4% of the patients received pro-
phylactic vaccinations (range 1–150 persons, median 3). 
Contacts were more frequently vaccinated in response to 
cases in nonadults (RR 1.594, 95% CI 1.374–1.849).
No large outbreaks were reported during the study. 
In the 13 participating states, 9 clusters with >5 infec-
tions were detected. The largest (13 symptomatic and 2 
asymptomatic infections) was in a school with multiple 
generations of infection. The ultimate source of infection 
could not be elucidated. The school index case-patient 
had not traveled. However, the implicated HAV strain 
was genetically similar to strains from Turkey. In 4 of the 
8 outbreaks with 5–7 infected persons, >1 travel-associat-
ed index cases were recognized, leading to 1–4 secondary 
infections in Germany.
Detection of HAV RNA
HAV RNA was detected in 95 (50.3%) of 189 samples 
matching a reported case of symptomatic HAV infection. 
The likelihood of detecting HAV RNA in serum depended 
on clinical characteristics of patients (Table 5). Frequency 
of RNA detection increased with number of symptoms 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 11, November 2009  1763 
Table 3. Travel characteristics of 346 patients infected with 
hepatitis A virus, Germany, 2007–2008 
Characteristic No. (%) patients 
Destination
 Turkey  89  (35.6) 
 Former  Yugoslavia  24  (9.6) 
 Egypt  18  (7.2) 
 Spain  15  (6.0) 
 Pakistan  10  (4.0) 
 Morocco  7  (2.8) 
 Others  86  (34.5) 
 All  249  (99.7) 
Duration of travel, d 
 1–14  51  (22.7) 
 15–29  62  (27.6) 
 30–180  112  (49.8) 
 All  225  (100) 
Type of travel 
  Visiting friends or family  149 (63.9) 
  Other Vacation  79 (33.9) 
 Business  5  (2.1) 
 All  233  (100) 
Type of accommodation 
 Private  141  (73.1) 
  Hotel or cruise ship  52 (26.9) 
 All  193  (100) 
Figure 1. Reported cases of hepatitis 
virus A infection (n = 679) by month 
of onset and patient age group (y), 
Germany, 2007–2008. A) Imported 
cases. B) Nonimported cases. RESEARCH
reported (p<0.02) and was negatively associated with pa-
tient age (p<0.001). Although this frequency was similar 
for nonadults and adults <39 years of age (mean 65%), 
RNA was detected in only 10% of symptomatic patients 
>60 years of age. No correlation was seen between duration 
from symptom onset to day of blood sampling (maximum 
29 days) and positive results for HAV RNA.
Molecular Epidemiology
A PCR-generated 348-bp fragment was available 
for analysis of isolates with detectable HAV RNA from 
126 patients. Of these patients, 73 (57.9%) had genotype 
IB strains, 36 (28.6%) had genotype IA strains, and 17 
(18.6%) had genotype IIIA strains. Sequences differed in 
<8.9%, <7.5%, and <4.9% of positions within genotype IB, 
IA, and IIIA strains, respectively. Sequence variability was 
reﬂ  ected in the diversity of countries or regions from which 
sequences originated (Figure 3).
Phylogenetic analysis showed that imported strains 
clustered according to region or country. Imported geno-
type IB strains were isolated from patients who traveled 
to Turkey, the Middle East, and Africa. Strains acquired 
in South Africa formed a small but distinct subcluster. Pa-
tients infected with genotype IA strains reported traveling 
to eastern Europe, Asia, South America, and northwestern 
Africa. The small number of imported genotype IIIA strains 
was obtained from patients who had traveled to eastern and 
southeastern Europe and Central and southern Asia. Three 
strains imported from Spain (2 genotype 1A and 1 genotype 
3A) were genetically more distant from each other than to 
strains from other regions (e.g., northern Africa).
Strains from patients with known migration back-
grounds (Figure 3) but no travel histories clustered with 
imported strains of the respective region. This ﬁ  nding was 
evident in a clade containing 35 highly related genotype 
IB strains, of which 14 were imported from Turkey. Of 23 
persons with a background of migration from Turkey and 
for whom sequence data were available, 18 (78%) were 
infected with strains that were found within this clade. 
Furthermore, among persons who traveled to Turkey and 
available information on possible migration background 
(n = 12), all also had a background of migration from Tur-
key. Strains isolated from patients with autochthonous in-
fections but without known migration backgrounds were 
nearly as genetically diverse as imported strains. Individ-
ual autochthonous strains, however, were frequently very 
homogeneous to individual imported strains.
Most (53.2%) HAV sequences obtained were found 
only once. Another 18.3% were isolated from smaller out-
breaks of hepatitis A, which had already been detected 
through routine surveillance (Figure 3). Remaining se-
quences (28.6%) were each seen 2 or 3 times without any 
known epidemiologic connection. The exception was a 
strain found in 12 patients who represented sporadic cases 
and smaller outbreaks. This strain is part of the clade from 
Turkey mentioned earlier; among autochthonous cases 
with this strain, no clustering of time or place of infection 
was apparent. 





































Figure 2. Age distribution (y) of 
persons with hepatitis A virus (HAV) 
infection by migration background 
and country where HAV infection was 
acquired (n = 520 with all 3 factors 
known), Germany, 2007–2008. 
Table 4. Characteristics of patients with imported and nonimported hepatitis A virus infections, Germany, 2007–2008* 
Characteristic
No. (%) patients with 
imported infections 
No. (%) patients with 
nonimported infections 
Total no. (%) 
infected patients  RR (95% CI) 
Migration background  161 (63.9)  66 (23.0)  227 (42.1)  2.43 (2.01–2.95) 
Male sex  180 (52.0)  194 (43.5)  374 (47.2)  1.21 (1.04–1.42) 
Age <18 y  169 (48.8)  110 (24.7)  279 (35.2)  1.76 (1.51–2.04) 
Age >60 y  26 (7.5)  140 (31.4)  166 (21.0)  0.31 (0.21–0.44) 
Part of case cluster  79 (29.5)  65 (21.8)  144 (25.4)  1.22 (1.00–1.49) 
<18 y of age with migration background  119 (91.5)  45 (57.7)  164 (78.8)  2.90 (1.73–4.88) 
*RR, relative risk; CI, confidence interval. Hepatitis A Infections, Germany, 2007–2008
Discussion
Detailed epidemiologic data for 70% of symptomatic 
cases reported in participating states during the study (60% 
of all cases) enabled us to characterize incident cases of 
HAV infection in Germany better than using routine sur-
veillance data alone. Although deaths from hepatitis A are 
rare, frequent hospitalization and work time missed by pa-
tients or adults caring for sick children emphasize the need 
to focus on hepatitis A.
Despite existing vaccination recommendations for 
travelers to countries with high or intermediate levels of 
endemicity for hepatitis A, >40% of cases were directly 
related to travel. Among these cases, persons with any 
migration background were overrepresented, especially 
those who had a background of migration from Turkey. 
The German Statistical Ofﬁ  ce in 2006 reported that 16% 
of adults and 26% of children (overall 19%) living in Ger-
many had a migration background, compared with 63.9% 
of our patients with imported cases. Among those with a 
migration background who lived in Germany, 22% were 
from Turkey (9), but 48.5% of the case-patients had a 
Turkish migration background.
Among persons with infections imported from Turkey, 
92% had a migration background even though Turkey is 
also a popular travel destination for persons from Germany 
without a migration background. These ﬁ  ndings are consis-
tent with surveillance data from Denmark, which show that 
80% of travel-associated hepatitis A cases during 2002–
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Table 5. Serum samples positive for hepatitis A virus RNA by 
patient and disease characteristics for reported cases with 
symptomatic infections, Germany, 2007–2008 
Characteristic
No. samples, 
n = 189 
No. (%)  positive 
samples, n = 95 
Patient age, y 
 <1–9  44 30  (68) 
 10–19  32 20  (63) 
 20–39  43 28  (65) 
 40–59  39 14  (36) 
>60 31 3 (10)
Sex 
 M  102 55  (54) 
 F  87 40  (46) 
Signs and symptoms 
  Abdominal pain  83 40 (48) 
 Fever  73 45  (62) 
 Jaundice  115 69  (60) 
  Increased transaminase  
 levels 
83 39 (47)
No. above items reported 
 1  53 27  (51) 
 2  98 43  (44) 
 3  27 20  (74) 
 4  6 5  (83) 
Probable place of infection 
 Germany  115 49  (43) 
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Figure 3. Neighbor-joining phylogenetic tree of a 348-bp section 
of the viral capsid protein 1//2A junction region of hepatitis A virus 
(HAV) constructed by using the Kimura 2-parameter distance 
model. Place of infection (A), migration background (B), and age of 
case-patients (, 0–9 y; , 10–19 y; , 20–39 y; , 40–
59 y; , >60 y) (C) are shown for each HAV isolate. Linked 
cases as judged by health departments are indicated by brackets. 
HAV subgenotypes are indicated by roman numerals and letters. 
Scale bar indicates nucleotide substitutions per site.RESEARCH
2006 occurred in immigrants or children of immigrants, of 
whom 78% had acquired the disease while visiting their 
ancestral country (10).
Persons who travel to visit friends and family abroad 
are at greater risk for many preventable infectious dis-
eases than persons traveling for other purposes, such as 
tourism (11). This higher risk for patients with migration 
backgrounds may be associated with regions visited. For 
example, persons who live on the Aegean coast of Turkey 
have lower prevalences of antibodies against HAV, which 
is indicative of the current level of HAV circulation, than 
do persons who live in eastern Anatolia, where many im-
migrant families have their roots (12).
Travelers who had stayed at private lodgings, vis-
ited friends or family, and traveled longer appeared to be 
overrepresented among cases. This result is supported by 
several studies, which demonstrated that persons planning 
visits to friends and relatives are less likely than other 
travelers to be vaccinated against HAV (13–15). Low 
vaccination coverage may be caused by lack of aware-
ness by patients and physicians that when visiting friends 
and family in a hepatitis-endemic area, a vaccination be-
fore travel is recommended. Older persons with migration 
backgrounds may be immune to HAV because of previ-
ous exposure during childhood in their country of origin, 
but younger persons with migration backgrounds require 
vaccinations to acquire immunity. Persons with migration 
backgrounds, similar to friends and relatives they are vis-
iting, may not be aware of hepatitis A because in many 
areas to which this disease is endemic, most infections 
occur in early childhood, and hepatitis A is rarely detect-
ed. Lower food safety standards for home cooking and 
contact with children in whom the virus circulates may 
facilitate acquisition of HAV by travelers when they stay 
with friends and family.
Population groups with a higher risk for acquiring HAV 
infection abroad are also more likely to acquire secondary 
infections. Molecular and questionnaire data showed that 
geographic origin of HAV strains most often matched the 
origin of patients with imported and autochthonous cases. 
These ﬁ  ndings indicate that cases are imported by persons 
who visit home countries and that at least limited autoch-
thonous spread of cases occurs among close contacts. Chil-
dren of migrants born and raised in countries with low in-
cidences of hepatitis A and who have no previous exposure 
and immunity to HAV can facilitate introduction of HAV 
into large households and the general community through 
schools or childcare facilities (e.g., outbreaks in Denmark 
[16] and the Netherlands [17]). In the Netherlands, hepatitis 
A immunization campaigns speciﬁ  c for children traveling 
to hepatitis A–endemic areas have proven to be useful for 
reducing the incidence of HAV infections among persons 
with migration backgrounds and others (18). Using vacci-
nation to protect those at risk for primary infections while 
abroad would also preclude secondary spread in Germany. 
Phylogenetic analysis of HAV sequences obtained 
showed a greater diversity of strains than that reported in 
a similar study in Amsterdam, the Netherlands (19). The 
3 major genotypes were found in Germany. Within these 
genotypes, only limited relatedness but many unique 
strains were observed. As described in another study, HAV 
strains clustered according to geographic origin. This pat-
tern is compatible with patterns from countries with a low 
incidence of HAV, where no or limited transmission occurs 
outside risk groups and most infections are caused by im-
portation from areas outside the countries (20).
The largest cluster of strains observed was that of sev-
eral highly related genotype IB strains. This cluster includ-
ed only strains from cases imported from Turkey or nonim-
ported cases from patients with a background of migration 
from Turkey. These strains were obtained throughout Ger-
many during several months. Thus, relatedness may reﬂ  ect 
endemicity to Turkey rather than endemic spread among a 
speciﬁ  c population in Germany.
Lack of distinct clusters containing predominantly 
autochthonous cases suggests that supraregional, unrecog-
nized outbreaks did not occur during the study. Although 
infections secondary to imported cases may be frequent, 
especially in the immediate vicinity (household, family) 
of a case-patient, infection chains quickly terminate. This 
ﬁ  nding is also likely to result in part from satisfactory hy-
gienic conditions in Germany but is also likely a result 
of effective tracing and vaccination of case-contacts by 
local health departments. Although the exception, larger 
outbreaks in daycare centers (21), those caused by food 
products (22), and those among men who have sex with 
men (23) are likely to be detected through routine surveil-
lance. The largest outbreak detected in Germany in recent 
years involved tourists who had stayed at the same hotel 
in Egypt and was caused by consumption of contaminated 
orange juice (24).
The results of our study also provide information on 
speciﬁ   city of surveillance data. Especially among older 
hospitalized patients, frequently without jaundice, IgM-
positive serum samples were mostly negative for HAV 
RNA, which suggests false-positive serologic results. HAV 
IgM–positive samples that showed negative results by re-
verse transcription–PCR probably showed false-positive 
HAV IgM results for patients with persisting HAV IgM 
(25), cross-reactions in the test (e.g., in acute-phase infec-
tions with Epstein-Barr virus [26]), or nonspeciﬁ  c poly-
clonal activation of memory cells (27). As a bias favoring 
stability, this overestimate of numbers of cases has limited 
consequences for surveillance purposes. However, for the 
individual patient, speciﬁ   city of IgM in serum samples 
should be strongly considered.
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The main conclusion of this study is that existing vac-
cination recommendations for travelers to areas endemic 
for hepatitis should be emphasized. Furthermore, immuni-
zation of travelers should be made more accessible to risk 
groups through information campaigns and removal of ﬁ  -
nancial barriers (insurance payments for pretravel advice 
and vaccinations are not universal). If removal of these 
barriers to vaccination of all travelers is unlikely, the gen-
eral vaccination of children against HAV should be consid-
ered, given the high number of imported infections among 
children and the evidence of secondary autochthonous 
transmission.
Efforts to communicate recommendations to previously 
unaware population groups, especially, but not exclusively, 
persons with migration backgrounds, have the capacity to 
strongly reduce the number of HAV infections in Germany. 
However, as long as vaccination recommendations are ap-
plied only to travelers and overall immunity in the popula-
tion remains low or decreases further, risk for secondary 
transmission of imported infections remains high.
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